Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI) is Ocular’s leading investigational candidate for retinal diseases, based on its proprietary ELUTYX™ (bioresorbable hydrogel) technology combined with potent tyrosine kinase inhibitor (TKI), axitinib. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).
